Tenapanor not checked
Ardelyx · RDX5791 · AZD1722
FollowEvery change as it happens, and a Monday email
Trials
2 active
16 in total
What this is
- How it works
- Sodium-Hydrogen Exchanger 3 Inhibitor FDA class
- How it’s given
- “Patients will receive tenapanor 50 mg BID (total of 100 mg daily)”In the company’s words, NCT07382167 on ClinicalTrials.gov
- Tested for
- Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C)
- Main trialPhase 3
- “This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.”In the company’s words, NCT07382167 on ClinicalTrials.gov
- Other names
- IBSRELA · RDX5791 · AZD1722 · KHK7791
Other drugs for Irritable Bowel Syndrome With Constipation (IBS-C)
- BrenipatideEli Lilly · Phase 2
- PlecanatideBausch Health Americas, Inc. · Phase 2
- NaldemedineShionogi · Phase 1/2
Coming up2
- 26 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 26 Feb 2027 | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | |
| Phase 3Enrolling by invitation | Jul 2031 | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C | |
| Phase 4Completed | 26 Jun 2021 | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP | |
| Phase 4Completed | 13 Oct 2021 | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia | |
| Phase 3Completed | 15 Nov 2019 | A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis | |
| Phase 3Completed | 10 Aug 2021 | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | |
| Phase 3Completed | 27 Sep 2021 | Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | |
| Phase 3Completed | 1 Dec 2021 | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis | |
| Phase 3Completed | 27 Jun 2022 | Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | |
| Phase 3Completed | 20 Aug 2026 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | |
| Phase 2/3Completed | 17 Jul 2019 | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy | |
| Phase 2Completed | 26 Nov 2019 | A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD | |
| Phase 2Completed | 3 Dec 2019 | Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients | |
| Phase 2Completed | 10 Dec 2019 | Dose-finding Study of KHK7791 in Hyperphosphatemia Patients | |
| Phase 2Completed | 7 Jul 2026 | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | |
| Phase 1Completed | 30 May 2024 | An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026